Business Information
The group's principal activity is to develop therapeutically and commerically valuable pharmaceutical products by leveraging its integrated discovery platform. This platform increases the speed, efficiency and quality of pharmaceutical product discovery and development. The platform includes model system genetics and comparative genomics, libraries of modified model organisms, specialized reagents, assay biology, informatics databases and software, mechanism of action technology, automated high-throughput screening. The group designs its research to identify novel genes and protiens that specify disease pathway in a therapeutically relevant manner. The technologies of the group are applicable to all industries such as pharmaceutical, diagnostic, agrochemical and agricultural industries.
|
|
Name |
Title
|
Email
|
| Stelios Papadopoulos | Co - Founder, Chmn. | N/A | | Michael Morrissey | Pres. - Research, Development | Available | | Peter Lamb | Sr. VP - Discovery Research, Chief Scientific Officer | Available | | D. Wagner | VP - Research, Exelixis Plant Sciences | N/A | | Frank Karbe | CFO, Exec. VP | Available
|
|
|
Year |
Sales |
Net Income |
| 2005 | 75,961 | (84,404) | | 2004 | 52,857 | (137,245) | | 2006 | 98,670 | (101,492)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
